JP Morgan Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $27

Benzinga · 2d ago
JP Morgan analyst Brian Cheng maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and lowers the price target from $31 to $27.